Unblinding in the lecanemab trial in Alzheimer's disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.The Cochrane database of systematic reviews · 2026
   Pooled it
2. Amyloid-beta-targeting monoclonal antibodies in early Alzheimer's disease: a cochrane review summary and appraisal for the neurological community.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
   Review
3. Considering challenges for the new Alzheimer's drugs: Clinical, population, and health system perspectives.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
   Article
4. Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
   Article
5. Estimated effects of amyloid reduction on cognitive change: A Bayesian update across a range of priors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
   Article
6. Reply: Unblinding in the lecanemab trial in Alzheimer's disease.Brain : a journal of neurology · 2023
   Article

Corrections and comments

• Commented on by
  Reply: Unblinding in the lecanemab trial in Alzheimer's disease.2023
• Comment on
  An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?2023

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as